NCT07182552View on ClinicalTrials.gov

Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

February 23, 2026

Study Completion Date

March 30, 2026

Conditions
TED
Interventions
DRUG

NTB003

NTB003 dose 1, dose 2, dose 3, dose 4

DRUG

Placebo

Placebo dose 1, dose 2, dose 3, dose 4

Trial Locations (1)

Unknown

Aerospace Center Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY